Effectiveness of topical and ablative therapies in treatment of anogenital warts: a systematic review and network meta-analysis

Samantha Barton,¹ Victoria Wakefield,¹ Colm O’Mahony,²,³ Steven Edwards¹

ABSTRACT

Objective To generate estimates of comparative clinical effectiveness for interventions used in the treatment of anogenital warts (AGWs) through the systematic review, appraisal and synthesis of data from randomised controlled trials (RCTs).

Design Systematic review and network meta-analysis of RCTs. Search strategies were developed for MEDLINE, Embase, the Cochrane Library and the Web of Science. For electronic databases, searches were run from inception to March 2018. The systematic review was carried out following the general principles recommended in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.

Participants People aged ≥16 years with clinically diagnosed AGWs (irrespective of biopsy confirmation).

Interventions Topical and ablative treatments recommended by the British Association for Sexual Health and HIV for the treatment of AGWs, either as monotherapy or in combination versus each other.

Outcome measures Complete clearance of AGWs at the end of treatment and at other scheduled visits, and rate of recurrence.

Results Thirty-seven RCTs met inclusion criteria. Twenty studies were assessed as being at unclear risk of bias, with the remaining studies categorised as high risk of bias. Network meta-analysis indicates that, of the treatment options compared, carbon dioxide laser therapy is the most effective for achieving complete clearance of AGWs at the end of treatment. Of patient-applied topical treatments, podophyllotoxin 0.5% solution was found to be the most effective at achieving complete clearance, and was associated with a statistically significant difference compared with imiquimod 5% cream and polyphenon E 10% ointment (p<0.05). Few data were available on recurrence of AGWs after complete clearance. Of the interventions evaluated, surgical excision was the most effective at minimising risk of recurrence.

Conclusion Of the studies assessed, as a collective, the quality of the evidence is low. Few studies are available that evaluate treatment options versus each other.

Trial registration number CRD42013005457

INTRODUCTION

In 2013, global annual incidence of anogenital warts (AGWs) was estimated to range between 160 and 289 per 100 000, with incidence peaking in men aged 25 to 29 years and women aged <24 years.¹ Arising from infection with human papillomavirus (HPV), predominantly types 6 and 11, AGWs are the most commonly diagnosed viral sexually transmitted infection.¹ AGWs can potentially clear without treatment, most likely in people who are immunocompetent, and some people may prefer to wait a period of time before starting treatment.

Other subtypes of HPV are associated with an increase in risk of developing anogenital cancers. Subtypes 16 and 18 are linked with increased risk of cervical cancer in women and account for an estimated 70% of all cervical cancers.² ³ In 2008, the UK Department of Health announced the introduction of an HPV immunisation programme against HPVs for girls aged 12 to 13 years starting in September of that year.⁴ Arising from infection with HPVs are available in the UK, a bivalent vaccine (Cervarix; GlaxoSmithKline) protecting against subtypes 16 and 18, and a quadrivalent vaccine (Gardasil; Sanofi Pasteur) that additionally protects against subtypes 6 and 11. Economical evaluation of the two vaccines led to the bivalent vaccine being chosen for the first 3 years of the immunisation programme.⁴ However, the UK Department of Health approved the use of the quadrivalent vaccine in 2012, and, in 2018, extended HPV vaccination to include
boys aged 12 to 13 years, starting in 2019. Given approval for use of the quadrivalent vaccine, it is expected that there will soon be a reduction in the number of cases of AGWs presenting at sexual health clinics equivalent to that observed in other countries. In Australia, which was one of the first countries to introduce a national vaccination programme with the quadrivalent vaccine, assessment of six sexual health clinics identified a considerable decline in the proportion of women aged under 21 years presenting with AGWs at the clinics, dropping from 11.5% in 2007 to 0.85% in 2011 (p<0.001).

Although a national HPV vaccination programme in the UK will reduce the number of people presenting with AGWs, not all women will receive the vaccination and, at this time, boys are not vaccinated. The need for effective treatments against AGWs remains. Treatments for AGWs available in the UK encompass clinician-applied destructive techniques and patient-applied topical treatments. Topical treatments that can be applied by the person with AGWs at home are imiquimod 5% cream and podophyllotoxin (available as a 0.5% solution and a 0.15% cream). Other topical treatment options applied by a clinician are trichloroacetic acid (TCA) and podophyllin, although the use of podophyllin is no longer recommended by British Association for Sexual Health and HIV (BASHH). Patient-applied topical treatments are increasingly prescribed, particularly for mild, early lesions, because of the convenience of use and the increased privacy for the patient.

Ablative methods that require administration by a clinician, such as electrosurgery (cautery, hyfrecation), cryotherapy and laser therapy act to debulk the visible lesions. Alternatively, a clinician may decide to use a combination of a topical treatment and an ablative therapy. People who are immunocompromised typically have a poorer response to the treatments available. The topical antiviral cream cidofovir (Vistide; Gilead), which is primarily used to treat cytomegalovirus retinitis, has been investigated as a potential treatment option for those with AGWs who are immunocompromised.

Treatment choice is typically decided after discussion between the treating clinician and the person with AGWs. A systematic review carried out in 2014 evaluating the clinical and cost-effectiveness of clinician and patient-applied treatments implemented network meta-analyses (NMAs) and identified that ablative techniques were typically more effective than topical applied interventions at completely clearing AGWs. In 2015, BASHH updated their guidance on management of AGWs to include Catephen (polyphenon E) 10% ointment. A systematic review focusing on topical treatments found that imiquimod 3.75% and 5% cream, podophyllotoxin 0.5% solution and gel and polyphenon E 10% and 15% ointment were more effective than placebo, but, because of the low quality of the identified evidence definitive conclusions were not possible. The review did not carry out a NMA. The research presented here is an update of the systematic review comparing ablative and topical treatments, and has been expanded to include polyphenon E 10% ointment. Topical interventions assessed are limited to those recommended by BASHHH.

**METHODS**

Electronic databases were searched (Ovid MEDLINE In-Process & Other Non-Indexed Citations, Ovid Embase and Cochrane Library) from inception to March 2018. Web of Science was searched from 2000 to March 2018. Search strategies were designed to include medical subject headings (MeSH) and text terms for AGWs, including ‘condyloma acuminata’ (the medical term for AGWs), and were tailored to each database. MeSH or text terms for interventions of interest were not included in the original search strategies. For the review reported here, the original searches were updated and new strategies devised to retrieve potentially relevant records of studies evaluating polyphenon E 10% ointment. Search filters designed to retrieve records based on study design were identified through the InterTASC Information Specialists’ Sub-Group search filter resource. Full details of the search strategy used to retrieve records from Ovid Embase is provided in online supplementary information 1. Bibliographies of previous overviews, guidelines and retrieved articles were manually reviewed for additional studies. Two researchers (SB and one of VW and CK) independently screened the titles and abstracts returned by the searches according to the prespecified eligibility criteria. In cases in which consensus could not be achieved, the full texts of potentially relevant studies were ordered. Two reviewers (SB and one of VW and CK) independently assessed full publications for inclusion. Discrepancies were resolved by discussion, with involvement of a third reviewer (SE) if consensus could not be reached. Methods for the review are reported in more detail in the published protocol (CRD42013005457) and were based on the principles published by the National Health Service Centre for Reviews and Dissemination.

**Patient and public involvement**

Patients were not directly involved in the development of the review update.

**Inclusion criteria**

Randomised controlled trials (RCTs) evaluating treatment of patients aged ≥16 years with clinically diagnosed AGWs (irrespective of biopsy confirmation) were included. The interventions of interest were topical treatments and ablative techniques, either alone or in combination. Topical treatments assessed were: podophyllotoxin 0.5% and 0.8% (both solution and cream), imiquimod 5% cream, TCAA, polyphenon E 10% and 15% (ointment) and cidofovir. Physical ablation methods evaluated were: cryotherapy (liquid nitrogen spray or cryoprobe), surgical excision (under local anaesthetic), electrotherapy (electrocautery, hyfrecator surgery) and laser therapy. The primary outcomes of interest to the
review were AGW clearance, both at completion of treatment (eg, up to 16 weeks for imiquimod) and at later time points after completion of treatment (eg, 3 months, 6 months) and recurrence rate. Other outcomes assessed were: time to complete clearance, volume of wart clearance (e.g., >50% clearance of original AGWs or >75% clearance of original AGWs), relief of symptoms during treatment, appearance of new warts during treatment, quality-of-life (QoL) as reported using a validated QoL rating scale (eg, EQ-5D, SF-36), adverse events and malignancy. RCTs were included if the interventions of interest were evaluated in a population with AGWs and compared with each other (alone or in combination), placebo or no treatment. Studies were excluded if none of the outcomes of interest was reported.

Data abstraction and quality assessment
After an initial pilot data extraction phase of 10 studies by two reviewers (SB and VW), during which the suitability of the standardised data extraction form was evaluated, one reviewer (various) extracted data from the remaining studies into a modified data extraction form, with validation of the data by a second reviewer (SB): the data extraction form is available in online supplementary information 2. Information extracted included details on study design and methodology, the baseline characteristics of the population and data on outcomes of interest. Discrepancies were resolved by discussion, with involvement of a third reviewer (SE) when necessary. In cases where limited information was reported, authors were contacted with a request for additional detail. Two reviewers independently assessed the quality of the clinical effectiveness studies (SB and one of various reviewers). Discrepancies were resolved by discussion, with involvement of a third reviewer when necessary. Study quality was recorded using the Cochrane risk of bias tool.15 16 Outcome-specific risk of bias was determined for the outcomes for which data were extracted.15 The three bias assessment categories used were low, unclear and high. A study was assessed as being at low risk of bias when all domains were assessed with low risk of bias. Assessment of at least one domain as high risk of bias led to overall rating as high risk of bias. In cases where no domain was assessed as high risk, but one domain was unclear, the overall risk of bias for the study was determined to be unclear.

Meta-analysis
The comparative clinical effectiveness of interventions was investigated using NMAs. The methods used for NMA followed the guidance described in the National Institute for Health and Care Excellence Decision Support Unit’s Technical Support Documents for Evidence Synthesis.17 18 NMAs were conducted using a Bayesian Markov chain Monte Carlo simulation in WinBUGS (V.1.4; MRC Biostatistics Unit, Cambridge, UK). To ensure convergence on the posterior distribution, analyses were based on 60 000 iterations after a ‘burn in’ of 60 000 iterations. Uniformed priors were implemented and no covariates were accounted for in the NMA. Fixed and random effects models were used for the primary and sensitivity analyses with the best fitting model chosen based on the deviance information criterion. To facilitate inclusion of interventions of interest, the network was extended to include podophyllin 20% to 25%. Data from multi-arm studies were adjusted to account for correlations in relative treatment effects.19 Effect estimate for dichotomous outcomes was OR, with accompanying 95% credible interval (95% CrI) using people as the unit of analysis. The probability of a treatment being the most effective at achieving complete clearance at the end of treatment was assessed using surface under the cumulative ranking (SUCRA).20 A 95% CrI can be interpreted as a 95% probability that the parameter falls within this range. If a 95% CrI does not include one this can, therefore, be interpreted as a statistically significant result (at the 5% level of significance). Analyses for clinical outcomes were based on studies of low, or unclear risk of bias. Sensitivity analyses included studies deemed to be at high risk of bias. Ablative techniques, such as cryotherapy and surgical excision, are widely recognised as being the most effective techniques to achieve complete clearance of AGWs and, in RCTs, are often applied until complete clearance is achieved. To evaluate comparative clinical effectiveness of treatments administered over a set time frame, studies evaluating ablative techniques applied until complete clearance were not included in the NMA for analysis of complete clearance at the end of treatment. Studies evaluating imiquimod 5% cream were included if treatment was applied three times per week for a prespecified duration. Imiquimod 5% cream can be applied for up to a maximum of 16 weeks per episode of AGWs. RCTs of any prespecified duration of treatment were included in the NMA.

RESULTS
Appraisal of the searches run in September 2014 for an earlier systematic review of clinical and cost-effectiveness11 resulted in the identification of 70 relevant articles describing 60 RCTs (figure 1). Re-assessment of the full text publications in line with the revised protocol led to the exclusion of 27 RCTs described in 37 articles. An update search identified five new RCTs (figure 1), of which four are included in the review, to give a total of 37 RCTs: characteristics of all included studies are available as online supplementary information 3, complete data extraction forms for the four studies added at update are provided in online supplementary information 4 and a list of studies excluded during review of full text is available in online supplementary information 5. A translation could not be obtained for one RCT published in Farsi that treated 30 women with cryotherapy and 30 women with podophyllin 25%.21 From the study abstract, it is unclear whether the study was truly randomised and whether the results are consistent with other studies evaluating cryotherapy versus podophyllin 25%.

Figure 1  Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram for original and update search. RCT, randomised controlled trial.

All studies enrolled people with AGWs, with most studies focusing on treatment of external AGWs: of the studies included in the NMA, three RCTs enrolled people with internal and external AGWs. Considering HIV status, only two studies included in the NMA enrolled those who were HIV-positive, with the remaining studies including people who were immunocompetent or not specifying whether HIV-status was assessed during recruitment. There was considerable variation across studies in eligibility criteria in terms of size and volume of AGWs. Some studies required only clinical diagnosis of AGWs for eligibility, whereas others specified a minimum and maximum number of AGWs, or a minimum AGW total surface area for inclusion (online supplementary information 2). Study size ranged from 12 people in the smallest study to 503 in the largest identified study.

In studies assessing ablative techniques, such as cryotherapy or electrocautery, one study evaluating electrotherapy and placebo in which active intervention was given until complete clearance of AGWs was excluded from the NMA assessing complete clearance at the end of treatment. Across studies evaluating topical interventions, treatment application schedule and duration of treatment were specified for patient-applied topical treatments, including imiquimod 5% cream and podophyllotoxin 0.15% cream. Studies evaluating topical treatments at the licensed dosing schedule were included in the review of clinical effectiveness.

Treatments compared directly in each of the identified studies, together with information on whether the study has been included in a NMA are presented in table 1.

Of the 37 identified RCTs, no study was deemed to be at an overall low risk of bias (online supplementary information 2, table 1). Twenty studies were considered to have unclear risk of bias, with limited reporting in the full publication on the methods implemented for random sequence generation, and concealment of allocation, together with lack of clarity on level of masking, being the predominant reason for categorisation of unclear risk of bias. Reported lack of masking of key trial personnel was the most common reason for assessment of high-risk of bias for the remaining 17 studies. Primary outcomes of the review are complete clearance of AGWs and recurrence, both of which are subjective in nature and open to assessment bias if the investigator is aware of treatment allocation. A key secondary outcome assessed is complete clearance at time points after the end of treatment, which might be of particular interest to those experiencing AGWs. Although it may not be feasible to mask key trial personnel to treatment allocation in studies comparing ablative versus topical treatments, masking...
Table 1  Direct comparisons evaluated in identified RCTs

<table>
<thead>
<tr>
<th>Direct comparisons relevant to scope included in any NMA (primary or sensitivity for any outcome)</th>
<th>Identified studies evaluating comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td>vs placebo</td>
<td></td>
</tr>
<tr>
<td>Cidofovir</td>
<td>Snoeck&lt;sup&gt;10&lt;/sup&gt; Matteelli&lt;sup&gt;8&lt;/sup&gt;</td>
</tr>
<tr>
<td>Imiquimod 5% cream</td>
<td>Arican&lt;sup&gt;36&lt;/sup&gt; Beutner&lt;sup&gt;36&lt;/sup&gt; Edwards&lt;sup&gt;37&lt;/sup&gt; Gilson&lt;sup&gt;34&lt;/sup&gt; Tying&lt;sup&gt;38&lt;/sup&gt;</td>
</tr>
<tr>
<td>Polyphenon E 10% ointment</td>
<td>Stockfleth&lt;sup&gt;25&lt;/sup&gt; Tatti&lt;sup&gt;39&lt;/sup&gt;</td>
</tr>
<tr>
<td>Podophyllotoxin 0.5% solution</td>
<td>Beutner&lt;sup&gt;40&lt;/sup&gt; Kirby&lt;sup&gt;41&lt;/sup&gt; Von Krogh&lt;sup&gt;42&lt;/sup&gt; Greenberg&lt;sup&gt;43&lt;/sup&gt;</td>
</tr>
<tr>
<td>Electrotherapy</td>
<td>Benedetti Panici&lt;sup&gt;22&lt;/sup&gt; –</td>
</tr>
<tr>
<td>Topical treatments vs each other</td>
<td></td>
</tr>
<tr>
<td>Podophyllotoxin 0.5% solution vs podophyllotoxin 0.15% cream</td>
<td>Lacey&lt;sup&gt;23&lt;/sup&gt; Strand&lt;sup&gt;44&lt;/sup&gt; Claesson&lt;sup&gt;45&lt;/sup&gt;</td>
</tr>
<tr>
<td>Podophyllotoxin 0.5% solution vs imiquimod 5% cream</td>
<td>Komericki&lt;sup&gt;46&lt;/sup&gt; –</td>
</tr>
<tr>
<td>Ablative treatments vs each other</td>
<td></td>
</tr>
<tr>
<td>Cryotherapy vs electrotherapy</td>
<td>Stone&lt;sup&gt;49&lt;/sup&gt; Simmons&lt;sup&gt;27&lt;/sup&gt;</td>
</tr>
<tr>
<td>Argon plasma coagulation vs electrotherapy</td>
<td>– Braga&lt;sup&gt;51&lt;/sup&gt;</td>
</tr>
<tr>
<td>CO&lt;sub&gt;2&lt;/sub&gt; laser therapy vs electrotherapy</td>
<td>– Ferenczy&lt;sup&gt;52&lt;/sup&gt;</td>
</tr>
<tr>
<td>Injectable treatment vs others</td>
<td></td>
</tr>
<tr>
<td>Cidofovir vs electrotherapy</td>
<td>Orlando&lt;sup&gt;9&lt;/sup&gt; Stone&lt;sup&gt;49&lt;/sup&gt;</td>
</tr>
<tr>
<td>Combination treatment vs monotherapy</td>
<td></td>
</tr>
<tr>
<td>Cryotherapy plus podophyllotoxin 0.15% cream vs cryotherapy alone</td>
<td>Gilson&lt;sup&gt;26&lt;/sup&gt; –</td>
</tr>
<tr>
<td>Argon plasma coagulation plus imiquimod 5% vs argon plasma coagulation alone</td>
<td>– Viazis&lt;sup&gt;53&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Additional comparisons included to strengthen NMA

<table>
<thead>
<tr>
<th>Identified studies evaluating comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td>Podophyllotoxin 0.5% solution vs podophyllin 20%–25%</td>
</tr>
<tr>
<td>Podophyllotoxin 0.15% cream vs podophyllin 20%–25%</td>
</tr>
<tr>
<td>Imiquimod 5% cream vs podophyllin 20%–25%</td>
</tr>
<tr>
<td>Cryotherapy vs podophyllin 20%–25%</td>
</tr>
<tr>
<td>Surgical excision vs podophyllin 20%–25%</td>
</tr>
<tr>
<td>Electrotherapy vs podophyllin 20%–25%</td>
</tr>
</tbody>
</table>

CO<sub>2</sub>, carbon dioxide; NMA, network meta-analysis; RCT, randomised controlled trial; TCAA, trichloroacetic acid.
the clinician(s) assessing outcomes would minimise the risk of bias for this domain.

Complete clearance

Fifteen studies formed the primary network on complete clearance of AGWs at the end of treatment and generated effect estimates for nine interventions and 36 comparisons (figure 2). By contrast, 27 studies were included in the sensitivity analysis, generating information on 13 interventions and 78 comparisons (figure 2). Analysis of model fit identified the random effects model to be the best fitting in the primary and the sensitivity analyses. Reporting of results focuses on effect estimates versus podophyllotoxin 0.5% solution for treatments recommended in the BASHH guidelines for management of AGWs (table 2). NMA indicated podophyllotoxin 0.5% solution to be statistically significantly more effective than imiquimod 5% cream (primary analysis: OR <1 favours podophyllotoxin 0.5% solution: OR 0.07; 95% CrI 0.001 to 0.36) at achieving complete clearance at the end of treatment: results from the primary analysis were supported by sensitivity analysis (table 2). Studies evaluating polyphenon E 10% ointment were deemed to be at high risk of bias, which precluded their inclusion in the primary analysis of outcomes. Sensitivity analysis found podophyllotoxin 0.5% solution to be statistically significantly more effective than polyphenon E 10% ointment (OR 0.03; 95% CrI <0.001 to 0.18) at achieving complete clearance at the end of treatment (table 2). No

Table 2  Effect estimates for complete clearance at the end of treatment (selected comparisons) and recurrence vs podophyllotoxin 0.5% solution

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Primary analysis</th>
<th>Sensitivity analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete clearance at end of treatment (OR &lt;1 favours podophyllotoxin 0.5% solution)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Podophyllotoxin 0.5% solution</td>
<td>N/A</td>
<td>79.7%</td>
</tr>
<tr>
<td>Imiquimod 5% cream</td>
<td>0.07 (0.001 to 0.36)</td>
<td>24.1%</td>
</tr>
<tr>
<td>TCAA 80%–90%</td>
<td>2.61 (0.001 to 10.61)</td>
<td>44.5%</td>
</tr>
<tr>
<td>Cryotherapy</td>
<td>0.78 (0.005 to 4.52)</td>
<td>49.2%</td>
</tr>
<tr>
<td>Cryotherapy plus podophyllotoxin 0.15% cream</td>
<td>7.16 (0.002 to 23.97)</td>
<td>60.1%</td>
</tr>
<tr>
<td>Surgical excision</td>
<td>2.75 (0.01 to 16.31)</td>
<td>64.2%</td>
</tr>
<tr>
<td>CO₂ laser therapy</td>
<td>95.41 (0.04 to 376.50)</td>
<td>92.3%</td>
</tr>
<tr>
<td>Podophyllotoxin 0.15% cream</td>
<td>–</td>
<td>0.68 (0.05 to 3.04)</td>
</tr>
<tr>
<td>Polyphenon E 10% ointment</td>
<td>–</td>
<td>0.03 (&lt;0.001 to 0.18)</td>
</tr>
<tr>
<td>Electrotherapy</td>
<td>–</td>
<td>13.51 (0.46 to 76.11)</td>
</tr>
<tr>
<td>Cidofovir</td>
<td>–</td>
<td>13.72 (0.04 to 81.66)</td>
</tr>
<tr>
<td>Recurrence (OR &gt;1 favours podophyllotoxin 0.5% solution)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imiquimod 5% cream</td>
<td>1.76 (0.05 to 9.00)</td>
<td>54.5%</td>
</tr>
<tr>
<td>Cryotherapy</td>
<td>4.42 (0.06 to 22.20)</td>
<td>33.5%</td>
</tr>
<tr>
<td>Surgical excision</td>
<td>0.75 (0.007 to 3.67)</td>
<td>90.3%</td>
</tr>
</tbody>
</table>

CO₂, carbon dioxide; N/A, not applicable; OR, odds ratio; SUCRA, surface under the cumulative ranking; TCAA, trichloroacetic acid.
other statistically significant differences were identified for other active interventions versus podophyllotoxin 0.5% solution in either primary or sensitivity analyses. In both the primary and sensitivity analyses, carbon dioxide (CO₂) laser therapy was found to be the treatment likely to be the ranked first for achieving complete clearance at the end of treatment, with a SUCRA of 92.3% and 91.7% in the primary and sensitivity analysis, respectively (table 2). Similarly, in the rankogram (graphical depiction of likelihood of achieving each rank) for the primary analysis of complete clearance at the end of treatment, of the nine interventions forming the network, CO₂ laser therapy has the highest probability of being ranked the most effective intervention (figure 3). Of the topical treatments assessed in the primary analysis, podophyllotoxin 0.5% solution was found to have the highest SUCRA and ranking, having the highest probability of being the most effective treatment to achieve complete clearance second to CO₂ laser therapy (table 2 and figure 3).

Considering complete clearance of AGWs at timepoints after completion of treatment, few identified studies reported clinical effectiveness data on this outcome. Some studies reported follow-up data for the subgroup of people achieving complete clearance at the end of treatment rather than the full study population. Complete clearance without recurrence is distinct from recurrence as the former accounts for people who clear within a few days of completion of treatment. Four studies reporting complete clearance evaluated at least 1 month after end of treatment for all those randomised were included in the NMA.²² ²⁶-²⁸ Two of the four studies were judged to be of unclear risk of bias,²² ²⁶ with the other two studies deemed to be at a high risk of bias²⁷ ²⁸ and, therefore, a NMA was feasible for only the preplanned sensitivity analysis. Five interventions were indirectly compared in the NMA: placebo or no treatment, imiquimod 5% cream (three times a week), cryotherapy, electrotherapy, cryotherapy plus podophyllotoxin 0.15% cream.¹¹ All four active interventions were associated with a statistically significant improvement in complete clearance without recurrence compared with placebo. However, there were no statistically significant differences between any of the active interventions for the outcome.¹¹

**Recurrence**

For analysis of recurrence, placebo was excluded from the primary NMA due to no people achieving complete clearance after treatment in most identified studies. The primary NMA included five studies,²⁹-³³ four of which assessed recurrence at 6 months of follow-up,²⁹-³¹ ³³ and the final study at 3 months after completion of treatment. The network evaluated comparative clinical effectiveness of cryotherapy, imiquimod 5% cream, podophyllotoxin 0.5% solution, podophyllin 20% to 25% and surgical excision. Random effects model was the better fitting model. When compared with podophyllotoxin 0.5% solution, the NMA identified no statistically significant difference between any of the comparisons. Assessment of SUCRA indicated that, of the five treatments evaluated, surgical excision was likely to be the most effective treatment for reducing risk of recurrence after complete clearance (table 2).
Secondary outcomes

No study was identified in the update reported here that provided new data for the secondary outcomes of volume of wart clearance, appearance of new warts during treatment and adverse effects, which were specified in the protocol. Therefore, re-analysis of the NMA presented in the first iteration of the systematic review was not necessary. Data on time to complete clearance, relief of symptoms during treatment or quality of life were not identified. Please refer to the original publication for reporting of results for secondary outcomes.

DISCUSSION
Main findings

Of the interventions included in the NMA, analysis suggests that CO2 laser therapy is the most effective treatment for achieving complete clearance at the end of treatment. However, the wide CrIs generated in the NMA should be considered when interpreting results. As discussed earlier, although it is widely recognised that ablative techniques, such as CO2 laser therapy, are highly effective at removing AGWs, patient preference is likely to be for a topical treatment that they can apply at home. Of the topical treatments recommended by BASHH, NMA identified podophyllotoxin 0.5% solution as having the highest ranking of patient-applied treatments for achieving complete clearance. In terms of recurrence, no statistically significant difference in risk of recurrence at a maximum follow-up of 6 months was found between podophyllotoxin 0.5% solution and any of cryotherapy, imiquimod 5% cream and surgical excision, with surgical excision identified as the most effective treatment for reducing risk of recurrence after complete clearance.

Limitations

A strength of the review is that the evidence base forming the basis of this report was identified through robust systematic review methodology. However, due to their open label nature, about half of the studies identified were judged to be at a high risk of bias, with uncertainty around the quality of the remaining studies due to limited reporting of trial methods in the full text publications. Despite identification of 37 studies, most treatments are compared within only one RCT. Additionally, differences in inclusion criteria were noted across studies, particularly in size and volume of AGWs at baseline, which is likely to result in clinical heterogeneity in evaluated populations and could explain the uncertainty noted in the results of clinical effectiveness, as evidenced by the wide CrIs. Moreover, data for some of the prespecified clinical effectiveness outcomes of interest (eg, relief of symptoms during treatment and quality of life) were not available from any of the identified studies. An additional limitation is lack of a translation for one RCT published in Farsi. However, it is unclear whether the study was truly randomised and whether the results would influence the findings from the NMA.

CONCLUSIONS

The implementation of a UK HPV vaccination programme for women that targets the subtypes associated with AGWs has led to a reduction in the number of people diagnosed with AGWs. However, ensuring that the programme is successful is not without its challenges. Not all eligible women will receive the vaccine, and, at this time, the programme does not include boys, and, thus, the need for effective treatments against AGWs remains. With the introduction of the vaccination programme, it is unlikely that further RCTs assessing clinical effectiveness of interventions against AGWs will be carried out, which makes this systematic review timely and highly relevant. Although a large number of RCTs evaluating treatment options for AGWs is available, as a collective, the evidence base is weakened by uncertainty around the quality of studies informing decisions on the effectiveness of individual interventions. Topical treatments that can be applied by the patient are the mainstay of treatment, but the evidence supporting use of imiquimod 5% cream, podophyllotoxin 0.5% solution and podophyllotoxin 0.15% cream is derived from small RCTs that are at a high risk of bias. Moreover, few data are available from direct head-to-head comparisons of treatments. New RCTs assessing comparative clinical effectiveness are unlikely, but, given the considerable psychological burden to the patient with AGW and the cost of treatment of AGWs, it would be beneficial to carry out a high quality study to compare directly the preferred treatment options to better inform decision-making.

Acknowledgements

Thanks to Natalie Masento and Charlotte Karrera for their contribution to the review of titles and abstracts for relevance of studies to the review. Thanks to Gemma Marcenik for her contribution to the validation of the network meta-analyses. Thanks also to Elizabeth Thurgar and Dr Nathan Mayura for their contribution to the original piece of research on which this review is based.

Contributors

SB and VW reviewed titles and abstracts for inclusion into the review. SB and VW evaluated full publications for inclusion in the review. VW carried out the network meta-analyses, which was validated by SE. SB and VW contributed equally to the drafting of this article. COM contributed clinical expertise throughout the project. SE and COM edited and commented on draft reports and read the final article.

Funding

The review reported here is an update and extension to independent research funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme (HTA 12/44). The views and opinions expressed in this report are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Competing interests

None declared.

Patient consent for publication

Not required.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
REFERENCES


43. Tunel A, Erbapaz M, Ozogoztasi O. An open-label comparative study to evaluate the efficacy and tolerability of imiquimod 5% cream


